Episode Details

AI governance in the pharmaceutical industry cannot begin after deployment.

By that point, critical decisions about data, accountability, human oversight, transparency, risk, and system behavior have already been embedded into the technology.

So the better question is:

What if ethics were designed into AI from the beginning?

In this episode of The GMP Insider, we explore the concept of Ethics by Design and why it could become a foundational pillar of responsible AI governance in pharmaceutical Quality.

Discussion topics include:

• Why AI governance must begin during system design
• Patient safety considerations when AI makes mistakes
• Transparency and understanding AI outputs
• Designing meaningful human oversight
• Data integrity and AI governance
• Identifying potential bias and unintended outcomes
• Defining accountability when AI contributes to decisions
• Managing AI and model changes throughout the lifecycle
• The evolving role of QA in AI governance
• Why policies alone may not be sufficient for complex AI systems

For GxP and other regulated environments, responsible AI requires more than a policy describing how technology should be used.

Organizations need governance principles embedded into the design, validation, deployment, monitoring, and change management lifecycle.

The objective shouldn't be to create another compliance checklist.

It should be to build systems with appropriate ethical guardrails from the start.

Because as AI becomes more complex, governance must become more intentional.

Define accountability before deployment.

Design for human oversight.

Protect data integrity.

Monitor continuously.

Engineer trust from the beginning.

The central question for pharmaceutical AI should not simply be:

"Can we use this technology?"

It should also be:

"Can we govern it responsibly—and can we trust the way it was designed?"

You cannot govern complexity effectively if ethics is treated as an afterthought.

From batch to patient — quality is everything.